Teleflex Incorporated (TFX)

Teleflex reported adjusted EPS of $3.67 in Q3 2025, exceeding analyst expectations, but lowered its revenue growth outlook due to lower order rates in its intra-aortic balloon pump portfolio. The stock price decreased by 42.76% over the last 12 months, and 13.4% in the past six months as of December 30, 2024. The stock had been trading below its 200-day and 50-day moving averages, indicating a bearish trend. The abrupt departure of CEO Liam Kelly led to a same-day drop in share price, followed by an investigation by Pomerantz LLP for potential securities violations or unlawful business practices.

There is an indication of demand seasonality for Teleflex's products and services, as revenue declined from Q4 2024 to Q1 2025, reflecting seasonal and operational impacts.

Teleflex, Inc. is an American provider of specialty medical devices used in critical care and surgical procedures, operating within the medical device manufacturing industry. The company aims to enhance patient safety, reduce procedure times, and improve healthcare efficiency. Teleflex offers products such as Vascular Access, Anesthesia, Respiratory Care, Cardiac Care, Surgical Instruments, Interventional Urology, Other Interventional Devices, OEM Products and Hemostatic Products.

Teleflex has a significant global presence, operating directly in over 40 countries and selling its products in more than 150 countries. The company's international footprint supports advanced manufacturing, research and development, sales and marketing, distribution, customer service, and clinical education programs. Key operational facilities in the United States include Jaffrey, New Hampshire; Mansfield, Massachusetts; Maple Grove, Minnesota; Plymouth, Minnesota; and Trenton, Georgia. Teleflex also has a significant presence in Europe, including a facility in Limerick, Republic of Ireland, which holds a Japan Accreditation Certificate for an Overseas Manufacturer of Medical Devices.

Teleflex's brand reputation has been significantly impacted by the abrupt departure of its CEO, Liam Kelly, followed by an investigation into the company for potential securities violations or unlawful business practices. This leadership shake-up and legal scrutiny can raise questions about governance and past disclosures, potentially affecting investor confidence and the company's standing.

Approximately 64.73% of Teleflex's stock is held by institutional investors, 0.42% by insiders, and 34.85% by public companies and individual investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., T. Rowe Price Investment Management, Inc., Janus Henderson Group Plc., Eaton Vance Management, AQR Capital Management, LLC, and State Street Global Advisors, Inc.